ES2229786T3 - Preparacion farmaceutica de moxifloxacina. - Google Patents

Preparacion farmaceutica de moxifloxacina.

Info

Publication number
ES2229786T3
ES2229786T3 ES99955906T ES99955906T ES2229786T3 ES 2229786 T3 ES2229786 T3 ES 2229786T3 ES 99955906 T ES99955906 T ES 99955906T ES 99955906 T ES99955906 T ES 99955906T ES 2229786 T3 ES2229786 T3 ES 2229786T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
moxifloxacin
oral administration
lactose
administration according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99955906T
Other languages
English (en)
Spanish (es)
Inventor
Patrick Bosche
Hans Friedrich Mahler
Claus Weisemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7889824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2229786(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Application granted granted Critical
Publication of ES2229786T3 publication Critical patent/ES2229786T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES99955906T 1998-11-10 1999-10-29 Preparacion farmaceutica de moxifloxacina. Expired - Lifetime ES2229786T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19855758 1998-11-10
DE19855758 1998-11-10

Publications (1)

Publication Number Publication Date
ES2229786T3 true ES2229786T3 (es) 2005-04-16

Family

ID=7889824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99955906T Expired - Lifetime ES2229786T3 (es) 1998-11-10 1999-10-29 Preparacion farmaceutica de moxifloxacina.

Country Status (41)

Country Link
US (1) US6610327B1 (https=)
EP (1) EP1128831B1 (https=)
JP (1) JP4809978B2 (https=)
KR (1) KR100650489B1 (https=)
CN (1) CN1149993C (https=)
AR (1) AR021074A1 (https=)
AT (1) ATE279193T1 (https=)
AU (1) AU745282B2 (https=)
BG (1) BG64974B1 (https=)
BR (2) BR9915208A (https=)
CA (1) CA2349161C (https=)
CO (1) CO5070571A1 (https=)
CU (1) CU23260B7 (https=)
CZ (1) CZ292069B6 (https=)
DE (1) DE59910858D1 (https=)
DK (1) DK1128831T3 (https=)
EE (1) EE04418B1 (https=)
ES (1) ES2229786T3 (https=)
HK (1) HK1042245B (https=)
HN (1) HN1999000183A (https=)
HR (1) HRP20010332B1 (https=)
HU (1) HU229065B1 (https=)
ID (1) ID29089A (https=)
IL (2) IL142642A0 (https=)
MA (1) MA26757A1 (https=)
MY (1) MY121114A (https=)
NO (1) NO319342B1 (https=)
NZ (1) NZ511554A (https=)
PE (1) PE20001304A1 (https=)
PL (1) PL194020B1 (https=)
PT (1) PT1128831E (https=)
RU (1) RU2230555C9 (https=)
SI (1) SI1128831T1 (https=)
SK (1) SK283936B6 (https=)
SV (1) SV1999000194A (https=)
TR (1) TR200101310T2 (https=)
TW (1) TW580388B (https=)
UA (1) UA72483C2 (https=)
UY (1) UY25792A1 (https=)
WO (1) WO2000027398A1 (https=)
ZA (1) ZA200103141B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
EP1663226A1 (en) * 2003-09-03 2006-06-07 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
CN1330306C (zh) * 2004-08-11 2007-08-08 深圳市天一时科技开发有限公司 莫西沙星明胶胶囊剂及其制备方法
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
PT2349220E (pt) * 2008-10-09 2012-10-11 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Utilização de solventes orgânicos na granulação húmida de moxifloxacina
WO2010066385A1 (de) 2008-12-08 2010-06-17 Ratiopharm Gmbh Kompaktiertes moxifloxacin
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
CN101890169B (zh) * 2009-11-16 2013-09-11 江苏亚邦强生药业有限公司 莫西沙星口服制剂及其制备方法
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
CN102247314A (zh) * 2011-01-12 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服固体制剂
EP2510929A1 (en) * 2011-04-11 2012-10-17 Innocoll Technologies Limited Methods for treating bacterial infection
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
RU2466718C1 (ru) * 2011-10-14 2012-11-20 Закрытое акционерное общество "Брынцалов-А" Фармацевтический препарат моксифлоксацина
US9358261B2 (en) 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
WO2013063271A1 (en) * 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Artemisinin and berberine compositions and methods of making
EP2770985A4 (en) 2011-10-25 2015-01-21 U S Phytotherapy Inc ARTEMISININE AND BERBERINE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
BR112014012994A2 (pt) * 2011-11-30 2017-06-13 Toyama Chemical Co Ltd tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CN102525982A (zh) * 2012-02-21 2012-07-04 天津市汉康医药生物技术有限公司 一种稳定的盐酸莫西沙星药物组合物
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN103768063B (zh) * 2012-10-19 2016-04-20 深圳信立泰药业股份有限公司 一种盐酸莫西沙星药物组合物及其制备方法
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
JPH01175936A (ja) * 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd 6.8−ジフルオロ−1−(2−フルオロエチル)−1,4−ジヒドロ−7−(4−メチル−1−ピペラジニル)−4−オキソ−3−キノリンカルボン酸を有効成分とする錠剤
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0449445A3 (en) * 1990-03-27 1993-08-25 Pfizer Inc. Preparation of beta-ketoesters useful in preparing quinolone antibiotics
TW209865B (https=) * 1992-01-10 1993-07-21 Bayer Ag
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino

Also Published As

Publication number Publication date
HK1042245B (zh) 2005-03-11
HU229065B1 (en) 2013-07-29
HRP20010332B1 (hr) 2011-01-31
SK6102001A3 (en) 2001-12-03
CO5070571A1 (es) 2001-08-28
EP1128831B1 (de) 2004-10-13
ATE279193T1 (de) 2004-10-15
CN1149993C (zh) 2004-05-19
UY25792A1 (es) 2001-08-27
PT1128831E (pt) 2005-01-31
SI1128831T1 (en) 2005-04-30
PE20001304A1 (es) 2000-12-30
HUP0104762A3 (en) 2002-10-28
NZ511554A (en) 2003-07-25
ID29089A (id) 2001-07-26
KR20010089424A (ko) 2001-10-06
WO2000027398A1 (de) 2000-05-18
MA26757A1 (fr) 2004-12-20
CN1325306A (zh) 2001-12-05
ZA200103141B (en) 2002-05-07
TW580388B (en) 2004-03-21
HRP20010332A2 (en) 2002-06-30
AR021074A1 (es) 2002-06-12
US6610327B1 (en) 2003-08-26
SV1999000194A (es) 2000-10-16
AU745282B2 (en) 2002-03-21
CZ20011652A3 (cs) 2001-08-15
BG105459A (en) 2001-12-29
DK1128831T3 (da) 2005-01-17
UA72483C2 (en) 2005-03-15
HK1042245A1 (en) 2002-08-09
IL142642A0 (en) 2002-03-10
DE59910858D1 (de) 2004-11-18
CA2349161C (en) 2008-01-29
BG64974B1 (bg) 2006-11-30
CZ292069B6 (cs) 2003-07-16
JP2002529415A (ja) 2002-09-10
BRPI9915208A (pt) 2001-07-31
HUP0104762A2 (hu) 2002-05-29
HN1999000183A (es) 1999-11-01
BRPI9915208B1 (pt) 2011-11-01
AU1267400A (en) 2000-05-29
MY121114A (en) 2005-12-30
NO20012248D0 (no) 2001-05-07
CA2349161A1 (en) 2000-05-18
RU2230555C2 (ru) 2004-06-20
SK283936B6 (sk) 2004-05-04
RU2230555C9 (ru) 2006-02-27
BRPI9915208B8 (pt) 2021-07-06
IL142642A (en) 2006-10-05
EE200100259A (et) 2002-12-16
BR9915208A (pt) 2001-07-31
NO20012248L (no) 2001-06-06
EP1128831A1 (de) 2001-09-05
NO319342B1 (no) 2005-07-18
KR100650489B1 (ko) 2006-11-28
EE04418B1 (et) 2005-02-15
PL194020B1 (pl) 2007-04-30
CU23260B7 (es) 2008-01-24
TR200101310T2 (tr) 2001-10-22
JP4809978B2 (ja) 2011-11-09
PL348112A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
ES2229786T3 (es) Preparacion farmaceutica de moxifloxacina.
US9433620B2 (en) Pharmaceutical compositions of lurasidone
US9018261B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
ES2587912T3 (es) Composición farmacéutica que comprende olmesartán medoxomilo y rosuvastatina o su sal
CZ268197A3 (cs) Farmaceutická kompozice stabilizovaná zásaditým činidlem
SK52295A3 (en) Stable extended release oral dosage composition
US20130004550A1 (en) Sustained-release solid preparation for oral use
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
ES2352299T3 (es) Composiciones farmacéuticas que contienen fumarato de quetiapina.
ES2895951T3 (es) Composiciones farmacéuticas que contienen doravirina, fumarato de tenofovir disoproxil y lamivudina
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
US20020037899A1 (en) Compositions containing an inhibitor of dihydrofolate reductase and a folate
EP2558079B1 (en) Ciprofloxacin dry syrup composition
AU2017251803B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
CN101461799A (zh) 一种稳定的普伐他汀药物组合物及其制备方法
US20170202777A1 (en) Solid preparation
HK40045152B (zh) 结晶丙二酸肾上腺素盐
HK1198466A1 (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions